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Abstract Antiretroviral therapy (ART) requires lifelong
daily oral therapy. While patient characteristics associated
with suboptimal ART adherence and persistence have been
described in cohorts of HIV-infected persons, these factors
are poor predictors of individual medication taking
behaviors. We aimed to create and test instruments for the
estimation of future ART adherence and persistence for
clinical and research applications. Following formative
work, a battery of 148 items broadly related to HIV
infection and treatment was developed and administered to
181 HIV-infected patients. ART adherence and persistence
were assessed using electronic monitoring for 3 months.
Perceived confidence in medication taking and self-re-
ported barriers to adherence were strongest in predicting
non-adherence over time. Barriers to adherence (e.g.,
affordability, scheduling) were the strongest predictors of
non-adherence, as well as 3- and 7-day non-persistence. A
ten-item battery for prediction of these outcomes (www.
med.unc.edu/ncaidstraining/adherence/for-providers) and a
30-item battery reflective of underlying psychological
constructs can help identify and study individuals at risk
for suboptimal ART adherence and persistence.
Keywords Adherence  HIV  Item response theory 
Measurement  Prediction
Introduction
Advances in antiretroviral therapy (ART) have signifi-
cantly improved the prognosis and quality of life of persons
living with HIV infection, and developments in therapeu-
tics, including fixed-dose combination formulations and
single tablet regimens, have simplified ART without
compromising efficacy. However, the success of ART
continues to hinge on adequate adherence and persistence
to these medications, which, at present, require lifelong
daily dosing.
Suboptimal adherence to treatment and care remains a
challenge for many patients, even in the era of modern
ART, and can lead to virologic failure, drug resistance, and
transmission of the virus [1–4]. Studies conducted in dis-
parate HIV-infected populations reveal that medication
taking behaviors can vary considerably, are complex, and
influenced by personal, institutional, and structural factors
[1, 2, 5–9]. Mental health challenges, substance abuse, poor
social support, unstable housing, denial, stigmatization,
regimen complexity, and cost have each been associated
with sub-optimal ART adherence [1, 2]. These correlates of
ART adherence, derived from cohort studies, are useful
when examining populations, but are imperfect predictors
of ART adherence at the individual level. Therefore,
clinicians are frequently left to rely on judgment and
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intuition when assessing the likelihood of a patient taking
their medication regularly—resulting in inaccurate pre-
dictions of patient adherence [10].
Using two scale development approaches, we aimed to
create and test an instrument that would allow clinicians
and researchers to estimate future adherence and persis-
tence to ART. We recruited a diverse sample of HIV-in-
fected outpatients receiving care and recruited patients in
clinics located in North Carolina, a state with the eighth
highest HIV prevalence rate in the United States. We
reasoned that this new instrument could be used to identify
patients/participants at risk for missing ART doses and,
therefore, could also identify candidates for interventions
to support adherence and prevent treatment failure.
Methods
Survey Development
The survey development process included three phases:
Formative, Instrument Development, and Instrument
Piloting and Testing. The University of North Carolina at
Chapel Hill (UNC-Chapel Hill) Biomedical Institutional
Review Board approved all phases.
Formative Phase
Individual semi-structured interviews were conducted with
21 stakeholders in North Carolina, including staff (e.g.,
physicians, nurses, social workers) at major HIV clinics
and AIDS service organizations, and state health officials
involved in HIV-related policy-making, to assess their
perspectives regarding challenges to ART adherence.
Subsequently, six focus groups were conducted among 56
HIV-infected patients who had been prescribed ART, and
were at least 18 years of age. Two focus groups were
organized in each of three geographically distinct areas of
North Carolina, including a major metropolitan center, a
smaller city, and a rural county. One focus group was
conducted in Spanish. Participants were recruited via flyers
placed in HIV clinics and community service organizations
located in these areas. The focus group guide was informed
by the stakeholder responses and the published literature on
ART adherence challenges and was designed to explore
attitudes regarding ART among those living with the virus.
Findings from the Formative Phase were previously
reported [11, 12].
Instrument Development Phase
Focus group data were coded and analyzed to identify
themes related to the experience of taking ART. The
identified themes were used to generate survey items—
statements that could be read or spoken to elicit a response.
In total, 94 Likert-type items with a five-point agreement
scale (1 = strongly disagree; 5 = strongly agree) and 11
contingency questions, which included an additional
response option of does not apply, were combined to create
a final battery of items. To gain a better understanding of
these items and how they might be understood by our
sample, cognitive interviews were conducted with 18 HIV-
positive patients receiving care at the University of North
Carolina (UNC) Infectious Diseases Clinic. The HIV
Treatment Adherence Self-Efficacy Scale (HIV-ASES)
[13] and a modified version of the AIDS Clinical Trials
Group Adherence Barriers Questionnaire (ACTG-ABQ)
(dichotomous yes/no responses were used instead of the
original four-point Likert scale) [14] were also adminis-
tered. At the end of this phase of instrument development,
148 items were included in a question battery for use in the
Instrument Piloting and Testing Phase.
Instrument Piloting and Testing Phase
The question battery was piloted with 60 HIV-infected
patients receiving care at one of four HIV treatment cen-
ters: the UNC-Chapel Hill Infectious Diseases Clinic, the
Wake County Early Intervention Clinic in Raleigh, the
Wake Forest Medical Center Infectious Diseases Clinic in
Winston-Salem, and the Regional Center for Infectious
Diseases in Greensboro. The inclusion criteria were as
follows: age 18 years or older, English speaking, able to
provide informed consent, receiving ART, not using a pill
box, and not residing in an institutional setting where
medications are directly administered. The derived instru-
ment is intended to be used in patients with unknown levels
of adherence. There was no adherence inclusion criterion
as a broad spectrum of pill-taking behaviors was sought to
allow for determination of item performance and discrim-
ination. Responses from patients with high levels of
adherence and persistence were necessary to identify
response patterns that are predictive of suboptimal adher-
ence. As with prior stages of the instrument development
process, participants were recruited using flyers placed in
HIV clinics and community service organizations. Inter-
ested patients called a research number and were screened
by a research associate not associated with the recruitment
clinics.
Following the survey piloting, minor wording changes
were made to the survey battery. An additional 121 patients
meeting the same inclusion criteria for the pilot were
recruited using identical procedures at the same four HIV
treatment centers to assess the predictive performance of
the items in relation to ART adherence and persistence. As
described in detail below, participants were followed for
cutoffs,[20 and[30% non-adherence. There is no con-
sensus regarding the threshold of optimal ART adherence.
Thus we chose to examine non-adherence rates of 20 and
30% and assume that those who take at least 80% of their
ART would be at low risk of treatment failure while those
who take less than 70% of their HIV medication would
have a substantially greater likelihood of failure to achieve
or maintain viral suppression.
ART non-persistence was examined using a 3- and
7-day threshold for permissible gaps. Non-persistence was
quantified as the number of times a participant failed to
open their bottle for three or more consecutive days (i.e.,
three zeros in a row); this measure was also quantified
using seven or more consecutive days of missed bottle
openings. We refer to these as ‘‘3-’’ and ‘‘7-day’’ non-
persistence, respectively.
MEMs data were analyzed using two approaches: (1) a
‘‘conservative’’ analysis in which no adjustment to the
recorded MEMs data were made; and (2) an ‘‘adjudicated’’
analysis in which MEMs data were censored based on
participant self-report of non-use of the MEMs cap. The
most common reasons for data censoring in the adjudicated
approach were intermittent use of a pillbox and pocketing
of doses (e.g., removing the evening dose of a twice a day
medication when taking the morning dose). Conservative
results were comparable to adjudicated results; unless
otherwise stated, the adjudicated results are shown.
Psychometric Analyses to Identify Reliable Item Subscales
Using Item Response Theory
To evaluate which items included in the Instrument Pilot-
ing and Test Phase comprise psychometrically sound
scales, we examined the factor structure of each scale as it
was blocked and presented to respondents on the baseline
survey. We used the software IRTPRO 2.0 [16] to compute
local dependence (LD) statistics for each item block from
the baseline survey. Large LD values for item pairs sug-
gested that those particular items share specific variance
above and beyond the other items in the survey block.
Clusters of items exhibiting large LD statistics suggested
possible underlying factors; we formed subscales based on
these suggested factors. We then calibrated the items and
scored respondents, such that each respondent had a single
item response theory (IRT) scale score for each subscale.
IRT scale scores represent responses to categorical and
ordinal items that have been transformed into a continuous
scale based on each specific response pattern.
Using item-level responses from baseline assessments,
we identified reliable subscales based on attitudes, self-
reported adherence behavior, and beliefs. To determine
which items within a subscale had the most desirable
psychometric properties, we examined trace lines and item
3 months during which ART adherence was assessed. The 
results from the combined samples from the piloting and 
testing phases (60 ? 121) are reported in this manuscript.
Study Procedures
Assessments: Instrument Piloting and Testing Phase
For this study phase, participants were screened by 
research associates who were not associated with the 
clinics from which participants were recruited. Those 
confirmed to be eligible completed a baseline study visit 
during which the battery of items was administered using a 
tablet computer that the participant used to indicate their 
responses. At the visit, an electronic medication monitoring 
cap (MEMs, Aardex Inc) was placed on one HIV medi-
cation bottle. The MEMs cap was placed preferentially on 
the antiretroviral that the patient self-reported as most 
demanding for them; typically this was the medication that 
required the greatest number of doses per day, number of 
pills per day, or largest pill.
After the baseline visit, participants were seen at a 
mutually agreed upon location where the study visit could 
be conducted safely and confidentially at monthly intervals 
for 3 months. ART adherence and persistence were asses-
sed by MEMs in the Instrument Piloting and Test Phase. 
The visual analog scale was used to assess baseline ART 
adherence among those entering the study on HIV therapy 
[15].
Demographic characteristics, self-reported health status, 
HIV and medical history, ART taking practices (i.e., pill 
box use, pocketed doses), motivation to adhere to ART, 
substance use, and depression were obtained at baseline by 
a trained project staff member via computer assisted patient 
interviewing (CAPI). At each follow-up visit, changes in 
health and medication were recorded.
Data Analytic Approach
Quantifying Adherence and Persistence
To assess a participant’s non-adherence, a ratio was cal-
culated as the total number of non-adherent days divided 
by the number of days the participant was monitored by 
MEMs cap. If the number of bottle openings matched or 
exceeded the expected dose frequency, then the daily 
adherence was considered a success. A participant with a 
scheduled, twice daily dose and only one bottle opening for 
the day was considered non-adherent for the day. The 
adherence estimates for the first and last days the MEMs 
cap use were excluded as the adherence data on these days 
would be partial. The adherence ratio (0–100%) was ana-
lyzed and suboptimal adherence was also defined using 2
discrimination parameters. Items with larger discrimination
parameters are better able to differentiate between people
across levels of the underlying factor; therefore, those
items with the greatest discriminating power were consid-
ered the strongest candidates for each subscale.
Statistical Analyses to Predict Medication Adherence
from Individual Items
To identify candidate scale items that could be strong
predictors of non-adherence and non-persistence, we also
fit penalized regression models using the multivariable
lasso selection procedure [17]. The lasso approach is useful
when there are many items to consider in a prediction
problem because it avoids model over-fitting. Models were
cross-validated and used to select the lasso penalization
tuning parameter for each model.
Two types of predictor variables were used in these
analyses, separately: (1) the 148 individual survey items;
and (2) the 12 IRT reliable subscales identified in the prior
IRT data analytic step. The 11 contingency survey items
were recoded into three categories prior to analysis (agree,
disagree/neutral, does not apply). To predict the non-ad-
herence ratio the count of non-adherent days was modeled
using Poisson lasso regression with natural-log transformed
number of MEMs monitored days included as the model
offset term. Non-persistence was analyzed as a binary
outcome (0 episodes vs. 1 or more episodes) and modeled
using logistic lasso regression. Likewise, binary outcomes
of non-adherence[20 or[30% were modeled with
logistic lasso regression. In total, the lasso selection was
conducted separately for five endpoints: (1) non-adherence
rate; (2) non-adherence[20%; (3) non-adherence[30%;
(4) 3-day non-persistence; and (5) 7-day non-persistence.
We used multiple imputation with fully conditional
specification. Ordinal items were imputed using predictive
mean matching, binary items were imputed with logistic
regression, and 3-category contingency items were imputed
with a generalized logit model. Adherence ratio, 3-day
non-persistence, and all fully-observed ordinal survey
items were included in the imputation models when fea-
sible. Models including individual survey items used ten
imputed datasets and individual predicted values were
calculated from the average predicted value over the ten
imputed datasets.
We summarized the predictive impact by ranking indi-
vidual items according to the number of times they were
selected by the lasso method across the five endpoints and
ten multiple imputed datasets. Individual items that ranked
within the top ten were selected for a final prediction
model. When lasso-selected items were identified, we
matched them to the reliable IRT subscales previously
created. We conducted Poisson regression (negative bino-
mial regression in the case of statistically significant over-
dispersion) and logistic regression to obtain predicted
values from combinations of the included IRT subscales
and their corresponding items. For non-adherence rate we
plotted the ‘‘predicted versus observed’’ rates, and the
proportion of predicted values within ±10% of the
observed rate is shown. For each binary outcome, we
examined the true positive rate (sensitivity) versus false
positive rate (1-specificity) in a receiver-operator charac-
teristic (ROC) curve and the area under the ROC curve
(AUROCC).
The study participant-specific relative odds of non-ad-
herence on weekends (Saturday or Sunday) as compared to
non-adherence on weekdays was estimated using mixed
effects logistic regression with a random intercept for each
participant. The ‘‘glmnet’’ package was used to conduct the
lasso analyses in R version 3.1.2; other statistical analyses
were conducted in SAS 9.3 or 9.4.
Results
Participant Characteristics and Disposition
Of 212 patients approached for enrollment to the Instru-
ment Piloting and Testing Phase, 181 (85%) consented,
entered the study, and completed a baseline survey. Eight
participants were excluded from the analysis cohort
because there was evidence they used a pill box and not
medication bottles on which the MEMs cap was placed
(n = 5) or did not complete the baseline survey (n = 3).
The remaining 173 (96% of 181) were considered eligible
for analysis. These participants were monitored by MEMs
cap for a median (Q1, Q3) of 92 (86, 97) days (10–90th
percentile: 75–102). A summary of the selected antiretro-
viral medications for the MEMS cap is provided in Sup-
plemental Table S1. The most common MEMS monitored
medications were tenofovir disoproxil fumarate (TDF)/
emtricitibine (FTC) (29%), TDF/FTC/efavirenz (22%), and
TDF/FTC/elvitegravir/cobicistat (12%).
Table 1 presents the characteristics of the study partic-
ipants. Most participants were African–American and
middle aged; slightly more than a third were women. At
study entry, all but two participants were already receiving
ART at the time of study entry, and almost 80% entered the
study with an HIV RNA level that was below the limit of
assay detection. The median duration of ART therapy was
8 years, and a variety of ART were prescribed, with two
thirds of patients reporting being on a once-daily regimen
and the remainder reporting being on twice daily regimens.
Nearly half of the participants reported a history of
depression or bipolar disorder.
Descriptive Findings for ART Adherence
and Persistence
Using the adjudicated MEMs approach (i.e., MEMs data
supplemented by respondent self-report), the mean non-
adherence rate (non-adherent days/monitored days) was
22% (SD, 25) over the course of the 3-month study, with a
median (Q1, Q3) of 13% (3, 33). With the conservative
approach (i.e., MEMs data only), the estimated non-ad-
herence rate was similar, with mean (SD) of 25% (26) of
days and median (Q1, Q3) of 15% (3, 37) of days. Using
the adjudicated approach, 39% of participants (68/173) had
a non-adherence rate[20% of days, and 27% of partici-
pants (47/173) had a non-adherence rate[30%. Patient-
specific odds of non-adherence were 30% higher on the
weekends compared to weekdays (estimated odds ratio
(OR) 1.30, 95% CI: 1.17–1.44).
Many participants persistently opened their MEMS cap
as prescribed, with zero episodes of non-persistence.
Nevertheless, at least one episode of non-persistence for
3 days or longer was recorded in 37% of participants (64/
173) during study follow-up, and 17% (29/173) had at least
one episode of non-persistence lasting 7 days or longer.
Table 1 Characteristics of study participant (n = 173)
Characteristic Statistics
Age (years)
Median (Q1, Q3) 48 (39, 53)






Race/ethnicity (check all that apply)




More than 1 race 6 (3%)
Education level
Less than high school 43 (25%)
High school 59 (34%)
College or beyond 70 (41%)
Insurance status (check all that apply)
Unemployed/disabled 104 (60%)
Insured for clinic visits 148 (86%)
Insured for medication 155 (92%)





Other government plan 12 (7%)
Other plan 24 (14%)
Years since HIV?diagnosis
Median (Q1, Q3) 12.6 (4.6, 18.5)
Min–max 0.0–30.4
Ever take HIV medications 168 (97%)
Number of ART medications
Median (Q1, Q3) 2 (1, 3)
Min–Max 0–5
Dosing frequency from self-report
Once daily 115 (68%)
Twice daily 54 (32%)
Dosing frequency from MEMs
Once daily 142 (82%)
Twice daily 31 (18%)
Years since ART start
Median (Q1, Q3) 8.2 (3.0, 15.6)
Min–max 0.0–28.3
Type of pharmacy (check all that apply)
Mail pharmacy 82 (48%)
Local pharmacy 70 (41%)
Table 1 continued
Characteristic Statistics
Clinic pharmacy 20 (12%)
Other pharmacy (e.g. home delivery) 9 (5%)
CD4 count (cells/mm3)
Median (Q1,Q3) 565 (350, 770)
Mean (SD) 605 (334)
Min–max 10–2097
HIV-1 RNA\50 copies/mL 132 (79%)
Adherence visual analog scale, past 30 days
Median (Q1, Q3) 100 (96, 100)
Mean (SD) 96 (12)
Min–max 0–100
Reported 100% on adherence visual analog scale 103 (61%)
Depression/bipolar diagnosis 79 (46%)
Participant characteristics were summarized with a complete-record
approach (missing data excluded). Missing data: age (n = 4), gender,
education level, insurance status, number of ART medications, type
of pharmacy (n = 1 each), years since HIV diagnosis (n = 6), years
since ART start (n = 23), CD4 cell count (n = 9), HIV-1 RNA
(n = 5), and adherence visual analog scale (n = 4)
Findings from the Psychometric Analyses
of Subscales Using Item Response Theory
We conducted exploratory factor analyses, followed by
assessments of local dependence among item sets, which
resulted in 12 subscales from the baseline assessment with
moderate to large IRT marginal reliabilities. Appendix
Table 4 presents the 12 subscales along with their marginal
reliabilities. Descriptive analyses generally showed a neg-
ative skew, such that most participants endorsed the upper
portions of the scale corresponding to the ‘‘positive’’ set of
choices. Participants acknowledged the importance of
social support, cited positive reasons for medication (sub-
scale: Positivity), did not let the side effects prevent them
from taking the medications (Effects of Medication), and
reported trusting their doctors (Trust).
Findings from Predictive Adherence and Persistence
Models
For the adherence predictive models we considered 148
baseline survey items for inclusion in both the IRT sub-
scales and the predictive models of non-adherence and
non-persistence. For multivariable analyses of survey
items, data were imputed as described in the methods. Of
the reliable IRT subscales, HIV-ASES (confidence in
medication taking), ACTG-ABQ (barriers to adherence,
e.g. busy and forgetful), Difficulty, and Positivity each
included one item that ranked in the top ten according to
individual item lasso selection; these IRT subscales were
used to form prediction models (Table 2). When lasso
selection was applied directly to the 12 continuous IRT
scores ACTG-ABQ was selected across all five endpoints,
Difficulty was selected for four endpoints (not 7-day non-
persistence), and Positivity selected for the three adherence
endpoints. While HIV-ASES was never selected when fit
as an IRT score, the highest ranked individual predictive
item was from this subscale, and thus it was retained for the
final IRT-based prediction models. Additional IRT scores
ever selected by lasso were Mode (7-day non-persistence),
Convenience (3-day non-persistence), and Trust (3-day
non-persistence).
The two candidate surveys arising from this work,
Lasso-10 and IRT-30, are presented in Appendix Tables 5
and 6, respectively, and their internal prediction perfor-
mance is shown in Table 2. The Lasso-10 included the top
ten ranked items using lasso selection without regard to
IRT subscales (one item from HIV-ASES, one item from
ACTG-ABQ, and eight items novel to this work) with a
marginal reliability of.77. The IRT-30 contained 30 items
from four IRT subscales and had a marginal reliability
of.90. These two potential surveys have four items in
common. The ten-item survey takes approximately 5 min
to complete and the 30-item survey takes approximately
10 min (note the yes/no items were less time consuming
than those on a Likert scale). The top ten individual items,
according to lasso ranking alone, performed well with
respect to internal prediction (AUROCCs: 77–89%). A
calculator for predicted probability of non-adherence and
non-persistence outcomes using the items in Lasso-10, is
available online (www.med.unc.edu/ncaidstraining/adher
ence/for-providers), providing a short survey that would be
suitable in a clinical setting.
The final IRT prediction models included either the IRT
scores or items from HIV-ASES, ACTG-ABQ, Difficulty,
and Positivity (30 items total). Internal prediction of the
observed non-adherence ratio within a threshold of ±10%
was achieved for 37% of individuals when the 30-item
scale was fit using its four continuous IRT scores, and for
47% of individuals when fit using the 30 individual items
Table 2 Prediction of non-adherence and non-persistence
Endpoint Events/total AUROCC IRT scoresa Events/total AUROCC IRT 30b,c AUROCC Lasso 10c,d
Non-adherence[20% 66/169 .700 68/173 .861 .813
Non-adherence[30% 45/169 .766 47/173 .841 .846
Non-persistence 3-day 62/169 .633 64/173 .838 .766
Non-persistence 7-day 28/169 .696 29/173 .835 .886
4 df 30 df 13 df
HIV-ASES the HIV treatment adherence self-efficacy scale, ACTG-ABQ modified version of the AIDS clinical trials group adherence barriers
questionnaire, Difficulty, Positivity additional ESTEEM items created based on stakeholder and consumer interviews, AUROCC area under
receiver-operator characteristic curve, df degrees of freedom, IRT item response theory, Lasso least absolute shrinkage and selection operator
a HIV-ASES, ACTG-ABQ, Difficulty and Positivity fit as 4 continuous IRT scores; n = 169 (4 subjects with missing IRT scores excluded)
b HIV-ASES, ACTG-ABQ, Difficulty and Positivity fit using the 30 Likert-type survey items included in these IRT subscales
c n = 173, average AUROCC over ten imputations is shown
d Top ten items using lasso selection (includes three contingency items with three categories each, hence 13 df)
subscales, ACTG-ABQ (adherence barriers) was most
strongly associated with non-adherence (p-values\ .001)
and non-persistence outcomes (p-values = .02). A higher
ACTG-ABQ score was associated with greater odds of
both non-adherence and non-persistence (Table 3).
Discussion
Using a comprehensive scale development approach we
identified two new scales, both of which were reliable and
predictive of medication adherence and persistence among
a diverse group of patients living with HIV infection. Our
formative work included extensive interviews with service
health care providers and focus groups of people living
with HIV infection, and set a strong foundation upon which
Table 3 Association between IRT Scores and adherence and persistence (n = 169)
Rate ratio 95% CI Wald Chi square P value
Non-adherence rate
HIV-ASES 1.25 1.01 1.53 4.38 .04
ACTG-ABQ 1.61 1.25 2.07 13.51 <.001
Difficulty 1.08 0.86 1.35 0.40 .53
Positivity 0.86 0.69 1.08 1.66 .20
Odds ratio 95% CI Wald Chi square P value
Non-adherence[20%
HIV-ASES 1.11 0.76 1.61 0.29 .59
ACTG-ABQ 2.18 1.38 3.43 11.30 <.001
Difficulty 1.22 0.78 1.89 0.76 .38
Positivity 0.70 0.45 1.09 2.49 .11
Non-adherence[30%
HIV-ASES 1.44 0.93 2.25 2.65 .10
ACTG-ABQ 2.79 1.71 4.57 16.70 <.001
Difficulty 1.37 0.82 2.28 1.46 .23
Positivity 0.71 0.42 1.21 1.58 .21
3 day non-persistence
HIV-ASES 0.88 0.62 1.27 0.45 .50
ACTG-ABQ 1.67 1.08 2.58 5.27 .02
Difficulty 1.31 0.85 2.04 1.48 .22
Positivity 0.97 0.63 1.50 0.02 .89
7 day non-persistence
HIV-ASES 1.25 0.77 2.03 0.81 .37
ACTG-ABQ 1.87 1.11 3.13 5.55 .02
Difficulty 1.49 0.83 2.68 1.81 .18
Positivity 1.19 0.67 2.14 0.35 .55
Bold values indicate statistical significance
HIV-ASES the HIV treatment adherence self-efficacy scale, ACTG-ABQ modified version of the AIDS clinical trials group adherence barriers
questionnaire, Difficulty, Positivity additional ESTEEM items created based on stakeholder and consumer interviews
a Multivariable models were fit using continuous IRT scores for HIV-ASES, ACTG-ABQ, Difficulty and Positivity. A non-adherence rate ratio
was estimated using negative binomial regression (dispersion estimate = 1.33, 95% CI 1.07–1.65), and odds ratios were estimated using logistic
regression
from the IRT-30 scale (Supplementry Fig. S1). Looking at 
dichotomized outcomes with the selected IRT subscales fit 
as IRT scores, the AUROCC ranged from 63 to 77% across 
the dichotomized outcomes. There was numerically stron-
ger prediction when we fit the 30 chosen individual items 
(AUROCCs: 84–86%, as shown in Table 2) compared to 
fitting these same items using their respective IRT scores. 
We chose to keep IRT subscales intact within the final IRT-
30 survey because these items were calibrated as a set in 
the IRT analyses. The purpose of IRT is to define and 
evaluate scales based on sets of items measuring a common 
construct; selecting items from different subscales and 
combining them into a new scale changes the construct that 
is being measured. To preserve the original substantive 
interpretations of the subscales, we did not omit or shuffle 
items across the IRT subscales. Among the chosen IRT
to introduce a new candidate set of items to existing sets
from the literature.
The candidate items and previously existing items were
combined in a survey and measured in a cohort of patients
receiving HIV care and, in general, taking HIV therapy for
several years. Among these participants we found that
adherence to ART was suboptimal approximately one
quarter of the time, with 27% of participants missing doses
more than 30% of the days they were observed. Further,
17% had at least a week-long break in therapy during study
follow-up.
For prediction of suboptimal adherence and non-per-
sistence outcomes we identified a new ten-item scale using
the lasso variable selection method. Eight of the top ten
items for prediction of adherence and persistence were
novel to this study. This ten-item scale had marginal reli-
ability of.77, which is reasonable reliability for a scale of
this length, and had area under the ROC curve internal
prediction values of 84.6 and 88.6% for[30% non-ad-
herence and 7-day non-persistence, respectively. This new
scale takes approximately 5 min to complete and has
potential for future evaluation and clinical use.
When examining the ability of items derived from our
formative work and from the literature to predict lapses in
therapy, we found that those assessing perceived confi-
dence in medication taking and self-reported barriers to
adherence were strongest in independently predicting non-
adherence. Items related to barriers to adherence (e.g.,
affordability, integration with schedule and activities) were
best able to predict independently higher levels of non-
adherence, as well as 3- and 7-day non-persistence. Self-
reported adherence measured using the visual analog scale
[15] at study entry did not improve the predictive capability
of the selected multivariable models.
Unlike many scale development studies, we further
applied an in-depth IRT psychometric approach to identify
new item subscales that were both short and reliable. Using
this approach, we identified new IRT subscales and ulti-
mately a 30-item scale with high marginal reliability (.90)
and internal predictive capability (as measured by area
under the ROC curve) similar to our ten-item scale. This
30-item scale includes two previously existing subscales
plus two novel subscales and takes approximately 10 min
to complete. Arriving at and interpreting the psychologi-
cally meaningful construct is the IRT goal, while purely
predicting medication adherence and persistence outcomes
is the goal of the lasso method. Each approach contributes
unique information, and one would not necessarily expect
the two approaches to converge on the same sets of items.
When interpreted side by side, these two methods can help
identify which sets of items measure a common psycho-
logical construct, and which individual items are the
strongest predictors of adherence.
Interestingly, the IRT subscales derived from the for-
mative work were short and reliable, but were weaker at
predicting adherence and persistence as those previously
developed in other populations [13, 14]. This finding may
reflect a disconnect between what people living with HIV
report as being facilitators and barriers to adherence and
what actually influences medication taking. The longest of
our new IRT subscales had only six items, compared to 9
and 12 items in the ACTG-ABQ and HIV-ASES sub-
scales, respectively, also suggesting that our formative
work produced new items that spanned across several
psychological constructs. It should also be noted that the
IRT scales were formed not based on their ability to
predict adherence, but rather on the degree to which
responses on individual items co-vary to measure a
common psychological construct. While a set of items
measuring disparate constructs may predict medication
adherence well, these items do not necessarily produce a
unidimensional, reliable IRT subscale. To be considered
an IRT subscale, it is assumed that the same underlying
psychological construct influences the item responses
within the set. Likewise, the item set most predictive of
adherence (i.e., the ten-item scale identified using the
lasso approach) is not necessarily a set of items that forms
a psychologically meaningful construct.
A major strength of this investigation was the economic,
educational, racial/ethnic, and gender diversity of our
studied sample. In addition, this contemporary cohort tak-
ing HIV medications reflects the characteristics of patients
of the foreseeable future; most were on once-daily therapy.
This study had high retention rates, and there were rela-
tively little missing data. Our candidate items were
developed via extensive formative research conducted with
individuals not unlike those studied. In addition, items
from select instruments that had been previously reported
to be predictive were included in the survey battery. As
there is some variability in the methods used to estimate
adherence using MEMs, we opted to conduct analyses
using two approaches: a strict conservative use of the
MEMs cap openings such that only the MEMs data were
evaluated, and an adjudicated use that included ‘forgive-
ness’ for explained non-openings of the cap. We found the
difference between the two approaches to be minimal—a
finding that can provide guidance to future use and analysis
of MEMs data.
Aspects of the study that were strengths were also lim-
itations. The MEMS indices do not tell specifically that
medication was actually ingested but rather that a particular
medication bottle cap was opened. Other study limitations
include the fact that we cannot say which items would
perform best with an external set of data, as we used the
complete dataset to identify the predictive items and
sets. While our study sample size was relatively large, this
investigation would benefit from an external validation of
the final ten-item and 30-item inventories. Follow-up, on
study HIV RNA data were not uniformly available and
therefore could not be described. Finally, we tracked study
participants for 3 months; longer term patterns of medi-
cation adherence and persistence are worthy of additional
study.
In summary, as HIV therapy continues to require
daily self-administration of one or more oral medica-
tions, adherence and persistence to these therapies con-
tinues to be essential to treatment success and long term
well-being. We identified a series of questions that could
be used to elicit responses that would be predictive of
future ART adherence and persistence including a ten-
item battery of items most predictive of these outcomes,
as well as a 30-item battery reflective of the psycho-
logical constructs found to be the root of medication-
taking in this population. These batteries may be useful
to clinicians and researchers, respectively, and others
seeking to predict ART taking behaviors. The ability to
identify individuals at risk for suboptimal adherence can
be highly valuable in directing counseling and other
supportive measures to achieve and maintain control of
HIV.
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Table 4 Item content, number of items and marginal reliabilities for 12 item response theory (IRT) subscales




HIV-ASES/confidence: In the next 30 days, how confident are you that you can: 12 .75
1. Stick to taking your HIV medicines even when side effects begin to interfere with daily activities?
2. Integrate taking your HIV medicines into your daily routine?
3. Integrate taking your HIV medicines into your daily routine even if it means taking them around other
people who don’t know you are HIV-infected?
4. Stick to your HIV medicine schedule even when your daily routine is disrupted?
5. Stick to your HIV medicine schedule when you aren’t feeling well?
6. Stick to your HIV medicine schedule when it means changing your eating habits?
7. Continue with taking your HIV medicines even if doing so interferes with your daily activities?
8. Continue with the HIV medicines plan your physician prescribed even if your T-cells drop significantly in
the next 3 months?
9. Continue with the HIV medicines even when you are feeling discouraged about your health?
10. Continue with taking your HIV medicines even when getting to your clinic appointments is a major hassle?
11. Continue with taking your HIV medicines even when people close to you tell you that they don’t think that
it is doing any good?
12. Continue taking your HIV medicines even if it doesn’t make you feel better?
Social support 4 .83
1. I have some very close people in my life who would do almost anything for me
2. My support (friends, family) give me strong emotional support
3. I have friends who give me strong emotional support
4. I have family who give me strong emotional support
Well-informed/doctor-patient relationship 5 .75
1. It makes me feel strong when I get a positive health report from my doctor
2. I would tell the doctor if I weren’t taking my medication
Table 4 continued




3. I have come to accept my HIV diagnosis
4. I have learned a great deal from reading about HIV/AIDS
5. I am comfortable asking my doctor questions about my disease
Difficulty/interference of medication 5 .83
1. I have physical health problems that make it hard for me to take my HIV meds regularly
2. I have mental health problems that make it hard for me to take my HIV meds regularly
3. It is hard for me to keep track of my HIV meds
5. HIV medications interfere with my ability to have fun
Positivity about medication 4 .80
1. I feel pretty healthy when I take my HIV medications
2. When I take my HIV medications, I feel better about myself
3. Taking my HIV medications gives me hope
4. Taking HIV medication reminds me to take care of my personal health
Management of medication 3 .82
1. I’d take my HIV meds more consistently if my doctor(s) helped me figure out if I was actually ready to take
the HIV meds
2. I’d take my HIV meds more consistently if my doctor(s) told me more about the problems I might face with
getting my HIV pills (such as cost)
3. I’d take my HIV meds more consistently if my doctor(s) helped me balance taking my HIV meds with my
other health needs (e.g., heart, weight, mental health, substance abuse)
Effects of medication 3 .84
1. I’d take my HIV meds more consistently if my doctor(s) taught me how the HIV meds help me stay healthy
2. I’d take my HIV meds more consistently if my doctor(s) showed me how the HIV meds affect my lab/blood
results
3. I’d take my HIV meds more consistently if my doctor(s) were very clear with me about the side effects of
my HIV medication
Trust: do you trust your health care provider: 4 .55
1. To offer you high quality medical care?
2. To be more concerned about your health than the time, effort, and costs of treating you?
3. To prescribe the best HIV medications?




2. Didn’t get prescription; ran out of pills?
3. Busy doing other things (e.g., working, trying to survive, getting food)?
4. Having to wake up very early to go to work and no time to eat?
5. Was too busy at work, school, or home?
6. Didn’t want to bring my pills to social activities (restaurant, friend’s home)?
7. Wanted to have a free day without pills?
8. Lost track of time?
9. Didn’t have a good night sleep?
Pleasantness 3 .88
1. I’d take my HIV meds more consistently if the pills were more pleasant to take
2. I’d take my HIV meds more consistently if the pills were smaller.
3. I’d take my HIV meds more consistently if the pills tasted more like candy
Mode of administration 4 .76
1. I’d take my HIV medications more consistently if I could take the pills in a liquid form rather than tablets
2. I’d take my HIV medications more consistently if they were a shot instead of pills
3. I’d take my HIV medications more consistently if they were a shot taken once a month
Table 5 Final ten-item scale






1. In the next 30 days, how confident are you that you can continue with the
HIV medicines even when you are feeling discouraged about your
health?
Scale ranging from 0 (‘‘cannot do at all’’)
to 10 (‘‘completely certain can do’’)
ASES 1
2. In the past month, have you missed taking your HIV medications
because you forgot?
No/yes ABQ 3
3. I find it easy to take my HIV meds with the other medication I take (a) Strongly disagree,
(b) Disagree,
(c) Neither disagree nor agree,
(d) Agree,
(e) Strongly agree,
(f) Does not apply
New 7
4. I have reduced my illegal drug use because I am taking my HIV
medications
New 8
5. If I could stop taking illegal drugs, I would be able to take my HIV
medications regularly
New 2
6. People often make me feel badly about being HIV? (1) Strongly disagree,
(2) Disagree,




7. Taking pills everyday is not a big deal New 5
8. It is hard for me to keep track of taking my HIV meds New 6
9. Taking my HIV medications gives me hope New 9
10. I can count on my family and friends to make sure I am taking my HIV
meds consistently
New 10
HIV-ASES the HIV treatment adherence self-efficacy scale. ACTG-ABQ modified version of the AIDS clinical trials group adherence barriers
questionnaire. New items created based on stakeholder and consumer interviews in the present study. This ten-item survey has been ordered to
group items with similar response scales together. Lasso prediction rank is shown for research purposes, with #1 being the most predictive item in
the present study, as summarized over non-adherence and non-persistence outcomes
Table 4 continued




4. I’d take my HIV medications more consistently if I did not have to take them in a special way (e.g., with
food, on an empty stomach).
Convenience 6 .90
1. I’d take my HIV meds more consistently if I felt fewer side effects
2. I’d take my HIV meds more consistently if I had fewer pills to take
3. I’d take my HIV meds more consistently if the meds were cheaper
4. I’d take my HIV meds more consistently if they were dosed less frequently
5. I’d take my HIV meds more consistently if I had been told more about the side effects before taking the pills
in the first place
6. I had special dispensers to help me keep track of the pills
HIV-ASES the HIV treatment adherence self-efficacy scale, ACTG-ABQ modified version of the AIDS clinical trials group adherence barriers
questionnaire
Additional ESTEEM Items created based on stakeholder and consumer interviews. Item subsets were identified using exploratory analyses for
ordered categorical variables, measures of item dependence, item trace lines and information functions. Items were rated on a scale ranging from
1 = strongly disagree to 5 = strongly agree
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